Exploring potential biomarkers for lung adenocarcinoma using LC-MS/MS metabolomics

BACKGROUND: The average 5-year survival rate of lung adenocarcinoma patients is only 15% to 17%, which is primarily due to late-stage diagnosis and a lack of specific prognostic evaluations that can recommend effective therapies. Additionally, there is no clinically recognized biomarker that is effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Liang, Wei, Bing, Liang, Renji, Yang, Zhi, Xie, Shouzhi, Wu, Shengrong, You, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Retrospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177994/
https://www.ncbi.nlm.nih.gov/pubmed/32316791
http://dx.doi.org/10.1177/0300060519897215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177994/
https://www.ncbi.nlm.nih.gov/pubmed/32316791
http://dx.doi.org/10.1177/0300060519897215

Ejemplares similares